DelveInsight Business Research

DelveInsight’s “Bladder Pain Syndrome Market Insights, Epidemiology, and Market Forecast-2032“ report delivers an in-depth understanding of the Bladder Pain Syndrome, historical and forecasted epidemiology as well as the Bladder Pain Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Bladder Pain Syndrome market report provides current treatment practices, emerging drugs, Bladder Pain Syndrome market share of the individual therapies, and current and forecasted Bladder Pain Syndrome market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Bladder Pain Syndrome treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Bladder Pain Syndrome market.

Interstitial Cystitis (IC) also known as bladder pain syndrome or pelvic pain.

Some of the key facts of the  Bladder Pain Syndrome Market Report:

• The total diagnosed prevalent population of Interstitial Cystitis (IC) in the seven major markets was found to be 2,425,036  in 2021, wherein the diagnosed prevalent population of IC patients in the United States was found to be  1,567,149 in 2021.

• The prevalent population of IC in the United States was found to be 5,952,356 in 2021.

• IC can be divided into three types based on severity, namely, mild, moderate, and severe type. DelveInsight, after analyzing the severity-based data for IC found that in the United States, the number of cases of mild, moderate, and severe was 564,173, 783,574, and 219,401, respectively in 2021.

Key Benefits of the  Bladder Pain Syndrome Report:

• The report covers the descriptive overview of Bladder Pain Syndrome, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies

• Comprehensive insight has been provided into the Bladder Pain Syndrome epidemiology and treatment in the 7MM

• Additionally, an all-inclusive account of both the current and emerging therapies for Bladder Pain Syndrome is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape

• A detailed review of the Bladder Pain Syndrome market; historical and forecasted is included in the report, covering drug outreach in the 7MM

• The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Bladder Pain Syndrome market

Got queries? Click here to learn more about the  Bladder Pain Syndrome Market Landscape

 Bladder Pain Syndrome Overview

Interstitial Cystitis (IC), also called Painful Bladder Syndrome, is a chronic condition causing bladder pressure, bladder pain, and sometimes pelvic pain. The pain ranges from mild discomfort to severe levels. The bladder is a hollow, muscular organ that stores urine, which expands until it is full and then gives signals to the brain that it is time to urinate, communicating through the pelvic nerves; this creates the urge to urinate for most people. With IC, these signals get mixed up, and then patients feel the need to urinate more often and with smaller volumes of urine than most people. This condition most often affects women and can have a long-lasting impact on their quality of life. Although there is no cure, medications and other therapies may offer some relief.

Interstitial Cystitis can be of two types, namely, Non-Ulcerative and Ulcerative. Non-ulcerative type is found in 90% of the population suffering from IC. It is characterized by pinpoint hemorrhages called glomerulations. However, these are not specific to IC, and any inflammation of the bladder can give that appearance.

Bladder Pain Syndrome Epidemiological Insights:

• According to the Urology Care Foundation, since there is no standard technique to diagnose IC/BPS, it is often hard to estimate the number of people affected. IC/BPS is typically two to three times more common in women than in men, and data have shown the risk of it increases with age. However, as per the current estimate, symptoms of IC/BPS are present in 1–4 million men and 3–8 million women.

• The Interstitial Cystitis Association has demarcated that 3–8 million women in the United States may have IC, which is about 3–6% of all women in the US. On the other hand, 1–4 million men have IC as well. However, this number is likely lower than the true rate because IC in men may often be mistaken for another disorder, such as chronic prostatitis/chronic pelvic pain syndrome. The number of men often remains underdiagnosed or underestimated.

• A single-center descriptive observational epidemiological conducted by Mazeaud et al. (2019), reviewed 134 patients managed for IC/BPS between January 2010 and December 2016. The researchers quoted that IC is a complex disease with an estimated prevalence between 45–500 cases/per 100,000 women and 8–40 cases/per 00,000 men with a marked female predominance of 71% (96 out of 134).

Bladder Pain Syndrome Epidemiological Segmentation 

• Total Bladder Pain Syndrome prevalent cases 

• Total  Bladder Pain Syndrome gender-specific cases 

• Total  Bladder Pain Syndrome diagnosed cases 

• Total Bladder Pain Syndrome age-specific cases

• Total Bladder Pain Syndrome type-specific cases 

Bladder Pain Syndrome Market Outlook 

The Bladder Pain Syndrome market outlook of the report helps to build a detailed comprehension of the historic, current and forecasted Bladder Pain Syndrome market trends by analyzing the impact of current Bladder Pain Syndrome therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of the Bladder Pain Syndrome market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Bladder Pain Syndrome market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Bladder Pain Syndrome market in 7MM is expected to witness a major change in the study period 2019-2032.

The  Bladder Pain Syndrome market outlook of the report helps build a detailed comprehension 

Learn more by requesting for sample @  Bladder Pain Syndrome Market Trends

 Bladder Pain Syndrome Key Companies

• Seikagaku Corporation

• UCB Pharma

• AbbVie

• And many others

 Bladder Pain Syndrome Therapies

• SI-722

• Certolizumab pegol/Cimzia

• BOTOX

• And many others

Table of Contents

• Key Insights 

• Report Introduction 

• Executive Summary of  Bladder Pain Syndrome  

• Disease Background and Overview

• Epidemiology and patient population

• Bladder Pain Syndrome  Emerging Therapies

•  Bladder Pain Syndrome  Market Outlook

• Market Access and Reimbursement of Therapies

• Appendix

•  Bladder Pain Syndrome  Report Methodology

• DelveInsight Capabilities

• Disclaimer

• About DelveInsight

Click here to read more about  Bladder Pain Syndrome Market Insight

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Adya Kaul
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432, Las Vegas NV
City: Las Vegas
State: United States
Country: United States
Website: https://www.delveinsight.com